| Description | This product is an effective CD40 antagonist, which inhibit the interaction between CD40 and CD40L. The antibody recongises the conformational CD40 epitope. It has potential applications in the study of Crohn's disease. ABBV-323 inhibited CD86 upregulation on primary human B cells. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Epitope | conformational epitope |
| Neutralization Mechanism | Stabilize the dimer for CD40 receptor via novel contacts to LCDR1. |
| IC50 | 3.1 nM |
| EC50 | 3.7 nM |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Antagonist |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | CD40 |
| Alternative Name | CD40; CD40 molecule, TNF receptor superfamily member 5; p50; Bp50; CDW40; TNFRSF5; tumor necrosis factor receptor superfamily member 5; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); nerve growth factor receptor-related B-lymphocyte activation molecule |
| Gene ID | 958 |
| UniProt | P25942 |
| Research Area | Immunology |
